Singapore, Jun 25, 2009: Dr Reddy’s Laboratories, an emerging global pharmaceutical company from India has launched Bispec (Solifencin Succinate) in India. Used in the management of Over Active Bladder (OAB), Bispec is the best-in-class for OAB and has lesser incidence of dry mouth and constipation.

People suffering from OAB have a warning time of about 12 seconds. Solifencin Succinate helps increase the warning time to about 32 seconds. Bispec is available in tablet form, and in dosages of 5 mg and 10 mg.

The company release noted that the market size for products used in the treatment of OAB is about $4.01 million (Rs 194 million) growing at seven percent (source: ORG MAT April 2009). Solifencin acts by competitively inhibiting Acetyl choline from binding to cholinergic receptors present in the bladder. This reduces bladder contractions and improves warning time in over active bladder patients. Solifencin Succinate is highly receptor specific and has superior pharmacokinetic profile.